ATP-sensitive potassium channels and endogenous adenosine are involved in spinal antinociception produced by locus coeruleus stimulation

Bombax costatum enhances piroxicam's efficacy: Possible involvement of alpha-2 adrenergic receptor, opioidergic and arachidonic pathways

BACKGROUND

With increasing drug-herb combination and widespread use of Bombax costatum as analgesic in Africa, this research studies effects of Bombax costatum on piroxicam's efficacy and possible mechanisms of antinociception.

MATERIALS AND METHODS

In efficacy studies, four groups of mice were respectively treated with 1mL/kg distilled water, 400mg/kg Bombax costatum, 20mg/kg piroxicam and a combination of both. Acetic acid and hot plate were used to induce pain in mice while prostaglandin-E₂ and formalin were used to induce inflammation in rats. For mechanistic studies, different groups of mice were treated intraperitoneally with 2mg/kg naloxone, 1mg/kg yohimbine, 20mg/kg propranolol, 5mg/kg glibenclamide and 1mg/kg prazosin respectively. Two other groups were treated orally with 1mL/kg of the vehicle and 400mg/kg Bombax costatum respectively. 60minutes later, 10mL/kg of 0.6% acetic acid was administered via the intraperitoneal route and number of writhes were observed for 10minutes.

RESULTS

Concurrent administration of Bombax costatum and piroxicam decreased the number of writhes significantly (P≤0.001), increased reaction time with decreased paw diameter in comparison to control. Additionally, this drug-herb combination showed enhanced anti-nocipective efficacy than when administered singly. Also, pre-treatment with yohimbine and naloxone significantly (P≤0.01) inhibited the antinociceptive activities of Bombax costatum.

CONCLUSION

Bombax costatum posses antinociceptive and anti-inflammatory activities and may involve α-₂ adrenergic receptor, opioidergic and arachidonic pathways. In addition, Bombax costaum augments the efficacy of piroxicam and could be of clinical benefits if studied on man.

Antinociceptive activity of methanol extract of Chlorophytum alismifolium tubers in murine model of pain: Possible involvement of α2-adrenergic receptor and KATP channels

The tubers of Chlorophytum alismifolium are used in Nigerian Herbal Medicine for the management of diabetes mellitus, painful and inflammatory conditions. The antinociceptive activity has been validated but the mechanism of this activity is yet to be explored. This study therefore, aimed to investigate the probable mechanism(s) of the antinociceptive activity of C. alismifolium tubers using experimental animal model of pain. HPLC and GC-MS analyses were carried out on the extract. Antinociceptive activity was investigated using acetic acid-induced writhing response test in mice. Three groups of mice were orally administered distilled water (10 ml/kg), C. alismifolium (400 mg/kg) and morphine (10 mg/kg) 60 min before administration of acetic acid and the resulting writhing were counted for 10 min. To establish the probable mechanism(s) of action of C. alismifolium, separate groups of animals were pretreated intraperitoneally with naloxone (2 mg/kg), prazosin (1 mg/kg), yohimbine (1 mg/kg), propranolol (20 mg/kg) and glibenclamide (5 mg/kg) 15 min before C. alismifolium administration. HPLC chromatogram of the extract revealed seventeen characteristic peaks with retention times ranging between 2.1 and 7.4 min. Administration of C. alismifolium significantly (p < 0.01) reduced the mean number of writhes compared to control group. Pretreatment with yohimbine and glibenclamide significantly (p < 0.05 and p < 0.01 respectively) reduced the antinociceptive activity of extract-alone treated group. However, pretreatment with prazosin, naloxone and propranolol showed no effect on its analgesic activity. The findings from this research revealed the possible involvement of α₂-adrenergic receptor and K_ATP channels in the antinociceptive activity of Chlorophytum alismifolium tuber extract.

Pharmacological mechanisms involved in the antinociceptive effects of dexmedetomidine in mice

Dexmedetomidine (DEX) is a α₂ -adrenoceptor (α₂ -AR) agonist used as an anesthetic adjuvant and as sedative in critical care settings. Typically, α₂ -AR agonists release nitric oxide (NO) and subsequently activate NO-GMPc pathway and have been implicated with antinociception. In this study, we investigate the pharmacological mechanisms involved in the antinociceptive effects of DEX, using an acetic acid-induced writhing assay in mice. Saline or DEX (1, 2, 5, or 10 μg/kg) was intravenously injected 5 min before ip administration of acetic acid and the resulting abdominal constrictions were then counted for 10 min. To investigate the possible mechanisms related to antinociceptive effect of DEX (10 μg/kg), the animals were also pretreated with one of the following drugs: 7-nitroindazole (7-NI; 30 mg/kg ip); 1H-[1,2,4] oxadiazole [4,3-a] quinoxaline-1-one (ODQ; 2.5 mg/kg, ip); yohimbine (YOH; 1 mg/kg, ip); atropine (ATRO; 2 mg/kg, ip); glibenclamide (GLIB; 1 mg/kg, i.p.) and naloxone (NAL; 0.2 mg/kg, ip). A rotarod and open-field performance test were performed with DEX at 10 μg/kg dose. DEX demonstrated its potent antinociceptive effect in a dose-dependent manner. The pretreatment with 7-NI, ODQ, GLIB, ATRO, and YOH significantly reduced the antinociceptive affects of DEX. However, NAL showed no effecting DEX-induced antinociception. The rotarod and open-field tests confirmed there is no detectable sedation or even significant motor impairment with DEX at 10 μg/kg dose. Our results suggest that the α₂ -AR and NO-GMPc pathways play important roles in the systemic antinociceptive effect of DEX in a murine model of inflammatory pain. Furthermore, the antinociceptive effect exerted by DEX appears to be dependent on KATP channels, independent of opioid receptor activity.

Involvement of adenosine A1 and A2A receptors in (-)-linalool-induced antinociception

In recent studies performed in our laboratory we have shown that acute administration of (-)-linalool, the natural occurring enantiomer in essential oils, possesses anti-inflammatory, antihyperalgesic and antinociceptive effects in different animal models. The antihyperalgesic and antinociceptive effects of (-)-linalool have been ascribed to its capacity in stimulating the opioidergic, cholinergic and dopaminergic systems, as well as to its interaction with K+ channels, or to its local anaesthetic activity and/or to the negative modulation of glutamate transmission. Activation of A1 or A2A receptors has been shown to induce antinociceptive effects, and the possible involvement of adenosine in (-)-linalool antinociceptive effect, has not been elucidated yet. Therefore, in the present study, we have investigated the effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a selective adenosine A1 receptor antagonist and the effects of 3,7-dimethyl-1-propargilxanthine (DMPX), a selective adenosine A2A receptor antagonist on the antinociception of (-)-linalool in mice, measured in the hot-plate test. Both DPCPX (0.1 mg/kg; i.p.) and DMPX (0.1 mg/kg; i.p.) pre-treatment significantly depressed the antinociceptive effect of (-)-linalool at the highest doses tested. These findings demonstrated that the effect of (-)-linalool on pain responses is, at least partially, mediated by the activity of adenosine A1 and A2A receptors.